Affilin Molecules Selected against the Human Papillomavirus E7 Protein Inhibit the Proliferation of Target Cells

Journal of Molecular Biology

Volumn 390, Issue 4, 2009, Pages 710-721

  Mirecka, Ewa A ^a   Hey, Thomas ^b   Fiedler, Ulrike ^b   Rudolph, Rainer ^a   Hatzfeld, Mechthild ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Scil Proteins GmbH   (Germany)

Author keywords

Affilin; human papillomavirus; intracellular targeting; phage display; B crystallin

Indexed keywords

AFFILIN; BINDING PROTEIN; GAMMA CRYSTALLIN; MOLECULAR SCAFFOLD; PROTEIN E7; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOFLUORESCENCE; MAMMAL CELL; MOLECULAR LIBRARY; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; SEQUENCE ANALYSIS; UTERINE CERVIX CANCER; WART VIRUS; WILD TYPE;

HUMAN PAPILLOMAVIRUS; MAMMALIA;

EID: 67649359312     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.05.027     Document Type: Article

References (58)

1. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 (2005) 1126-1136
2. Binz H.K., Amstutz P., and Pluckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 23 (2005) 1257-1268
3. Binz H.K., and Pluckthun A. Engineered proteins as specific binding reagents. Curr. Opin. Biotechnol. 16 (2005) 459-469
4. Nygren P.A., and Skerra A. Binding proteins from alternative scaffolds. J. Immunol. Methods 290 (2004) 3-28
5. Azzazy H.M., and Highsmith Jr. W.E. Phage display technology: clinical applications and recent innovations. Clin. Biochem. 35 (2002) 425-445
6. Amstutz P., Binz H.K., Zahnd C., and Plückthun A. Ribosome Display. Vitro Selection of Protein-Protein Interactions Cell Biology-A Laboratory Handbook. 3rd edit. vol. 1 (2006), Elsevier Academic Press 497-509
7. Hoogenboom H.R. Selecting and screening recombinant antibody libraries. Nat. Biotechnol. 23 (2005) 1105-1116
8. Hosse R.J., Rothe A., and Power B.E. A new generation of protein display scaffolds for molecular recognition. Protein Sci. 15 (2006) 14-27
9. Hey T., Fiedler E., Rudolph R., and Fiedler M. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol. 23 (2005) 514-522
10. Gill D.S., and Damle N.K. Biopharmaceutical drug discovery using novel protein scaffolds. Curr. Opin. Biotechnol. 17 (2006) 653-658
11. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr. Opin. Biotechnol. 18 (2007) 295-304
12. Amstutz P., Binz H.K., Parizek P., Stumpp M.T., Kohl A., Grutter M.G., et al. Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins. J. Biol. Chem. 280 (2005) 24715-24722
13. Kawe M., Forrer P., Amstutz P., and Pluckthun A. Isolation of intracellular proteinase inhibitors derived from designed ankyrin repeat proteins by genetic screening. J. Biol. Chem. 281 (2006) 40252-40263
14. Amstutz P., Koch H., Binz H.K., Deuber S.A., and Pluckthun A. Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries. Protein Eng. Des. Sel. 19 (2006) 219-229
15. Koide A., Abbatiello S., Rothgery L., and Koide S. Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor. Proc. Natl Acad. Sci. USA 99 (2002) 1253-1258
16. Junqueira D., Cilenti L., Musumeci L., Sedivy J.M., and Zervos A.S. Random mutagenesis of PDZ(Omi) domain and selection of mutants that specifically bind the Myc proto-oncogene and induce apoptosis. Oncogene 22 (2003) 2772-2781
17. Ebersbach H., Fiedler E., Scheuermann T., Fiedler M., Stubbs M.T., Reimann C., et al. Affilin-novel binding molecules based on human gamma-B-crystallin, an all beta-sheet protein. J. Mol. Biol. 372 (2007) 172-185
18. Bloemendal H., de Jong W., Jaenicke R., Lubsen N.H., Slingsby C., and Tardieu A. Ageing and vision: structure, stability and function of lens crystallins. Prog. Biophys. Mol. Biol. 86 (2004) 407-485
19. Rudolph R., Siebendritt R., Nesslauer G., Sharma A.K., and Jaenicke R. Folding of an all-beta protein: independent domain folding in gamma II-crystallin from calf eye lens. Proc. Natl Acad. Sci. USA 87 (1990) 4625-4629
20. zur Hausen H. Papillomaviruses in human cancers. Proc. Assoc. Am. Physicians 111 (1999) 581-587
21. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 92 (2000) 690-698
22. Munger K., Baldwin A., Edwards K.M., Hayakawa H., Nguyen C.L., Owens M., et al. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78 (2004) 11451-11460
23. Duensing S., and Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int. J. Cancer 109 (2004) 157-162
24. Dyson N., Howley P.M., Munger K., and Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243 (1989) 934-937
25. Huh K., Zhou X., Hayakawa H., Cho J.Y., Libermann T.A., Jin J., et al. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 81 (2007) 9737-9747
26. Collins A.S., Nakahara T., Do A., and Lambert P.F. Interactions with pocket proteins contribute to the role of human papillomavirus type 16 E7 in the papillomavirus life cycle. J. Virol. 79 (2005) 14769-14780
27. Dyson N., Guida P., Munger K., and Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J. Virol. 66 (1992) 6893-6902
28. Helt A.M., Funk J.O., and Galloway D.A. Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. J. Virol. 76 (2002) 10559-10568
29. Zerfass-Thome K., Zwerschke W., Mannhardt B., Tindle R., Botz J.W., and Jansen-Durr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 13 (1996) 2323-2330
30. He W., Staples D., Smith C., and Fisher C. Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J. Virol. 77 (2003) 10566-10574
31. Longworth M.S., and Laimins L.A. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol. Mol. Biol. Rev. 68 (2004) 362-372
32. Munger K., Basile J.R., Duensing S., Eichten A., Gonzalez S.L., Grace M., and Zacny V.L. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20 (2001) 7888-7898
33. Balsitis S., Dick F., Dyson N., and Lambert P.F. Critical roles for non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis. Cancer Res. 66 (2006) 9393-9400
34. Choo C.K., Ling M.T., Suen C.K., Chan K.W., and Kwong Y.L. Retrovirus-mediated delivery of HPV16 E7 antisense RNA inhibited tumorigenicity of CaSki cells. Gynecol. Oncol. 78 (2000) 293-301
35. Accardi L., Dona M.G., Di Bonito P., and Giorgi C. Intracellular anti-E7 human antibodies in single-chain format inhibit proliferation of HPV16-positive cervical carcinoma cells. Int. J. Cancer 116 (2005) 564-570
36. Nauenburg S., Zwerschke W., and Jansen-Durr P. Induction of apoptosis in cervical carcinoma cells by peptide aptamers that bind to the HPV-16 E7 oncoprotein. FASEB J. 15 (2001) 592-594
37. Jiang M., and Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21 (2002) 6041-6048
38. Vives E., Brodin P., and Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (1997) 16010-16017
39. Munger K., Phelps W.C., Bubb V., Howley P.M., and Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63 (1989) 4417-4421
40. Sedman S.A., Barbosa M.S., Vass W.C., Hubbert N.L., Haas J.A., Lowy D.R., and Schiller J.T. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J. Virol. 65 (1991) 4860-4866
41. von Knebel Doeberitz M., Rittmuller C., Aengeneyndt F., Jansen-Durr P., and Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions. J. Virol. 68 (1994) 2811-2821
42. von Knebel Doeberitz M., Rittmuller C., zur Hausen H., and Durst M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int. J. Cancer 51 (1992) 831-834
43. Yasumoto S., Burkhardt A.L., Doniger J., and DiPaolo J.A. Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells. J. Virol. 57 (1986) 572-577
44. Caldeira S., de Villiers E.M., and Tommasino M. Human papillomavirus E7 proteins stimulate proliferation independently of their ability to associate with retinoblastoma protein. Oncogene 19 (2000) 821-826
45. Edmonds C., and Vousden K.H. A point mutational analysis of human papillomavirus type 16 E7 protein. J. Virol. 63 (1989) 2650-2656
46. Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., and Howley P.M. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am. J. Pathol. 119 (1985) 361-366
47. Baker C.C., Phelps W.C., Lindgren V., Braun M.J., Gonda M.A., and Howley P.M. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Virol. 61 (1987) 962-971
48. Greenfield I., Nickerson J., Penman S., and Stanley M. Human papillomavirus 16 E7 protein is associated with the nuclear matrix. Proc. Natl Acad. Sci. USA 88 (1991) 11217-11221
49. zur Hausen H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res. 49 (1989) 4677-4681
50. Munger K., Yee C.L., Phelps W.C., Pietenpol J.A., Moses H.L., and Howley P.M. Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J. Virol. 65 (1991) 3943-3948
51. Fiedler M., Muller-Holzner E., Viertler H.P., Widschwendter A., Laich A., Pfister G., et al. High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. FASEB J. 18 (2004) 1120-1122
52. Alvarez-Salas L.M., Benitez-Hess M.L., and DiPaolo J.A. Advances in the development of ribozymes and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses. Antiviral Ther. 8 (2003) 265-278
53. Yamato K., Yamada T., Kizaki M., Ui-Tei K., Natori Y., Fujino M., et al. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Ther. 15 (2008) 140-153
54. Tan T.M., and Ting R.C. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res. 55 (1995) 4599-4605
55. Mirecka E.A., Rudolph R., and Hey T. Expression and purification of His-tagged HPV16 E7 protein active in pRb binding. Protein Expression Purif. 48 (2006) 281-291
56. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
57. Graham F.L., and van der Eb A.J. Transformation of rat cells by DNA of human adenovirus 5. Virology 54 (1973) 536-539
58. Wigler M., Silverstein S., Lee L.S., Pellicer A., Cheng Y., and Axel R. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell 11 (1977) 223-232